Author | Harold J. Burstein, MD, PhD | OncLive

Author | Harold J. Burstein, MD, PhD

Articles

Dr. Burstein on the Treatment Landscape of HER2+ Breast Cancer

October 30, 2018

Harold J. Burstein, MD, PhD, senior physician, associate professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the treatment landscape of HER2-positive breast cancer.

Dr. Burstein on the Results of the APT Trial for HER2+ Breast Cancer

July 13, 2017

Harold J. Burstein, MD, PhD, senior physician, associate professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the results of the APT trial investigating adjuvant paclitaxel and trastuzumab (Herceptin) for node-negative HER2-positive breast cancer.

Dr. Burstein on the Follow-Up of APT Trial for HER2+ Breast Cancer

June 23, 2017

Harold J. Burstein, MD, PhD, senior physician, associate professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the 7-year follow-up of the APT trial investigating adjuvant paclitaxel and trastuzumab (Herceptin) for node-negative HER2-positive breast cancer.

Dr. Harold J. Burstein on CDK4/CDK6 Inhibitor Abemaciclib in Breast Cancer

August 07, 2016

​Harold J. Burstein, MD, PhD, Senior Physician, Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute discusses the results of MONARCH1, which looked at abemaciclib as monotherapy in patients with ER-positive breast cancer, after chemotherapy for advanced disease.

x